Written question asked by Oliver Heald (Conservative) on Wednesday, 3 July 2002, in the House of Commons. It was due for an answer on Thursday, 11 July 2002. It was answered by David Lammy (Labour) on Thursday, 11 July 2002 on behalf of the Department of Health.

Dept of Health

Question: To ask the Secretary of State for Health, if he intends to restrict the use of typical anti-psychotic drugs to a named patient basis. (Holding answer 8 July 2002).

Answer: Mr. Heald: To ask the Secretary of State for Health if he intends to restrict the use of typical anti-psychotic drugs to a named patient basis. [67967] Mr. Lammy: [holding answer 8 July 2002]: There are no plans to restrict the use of the traditional or typical anti-psychotic drugs to a named patient basis. The recently published guidance from the national institute for clinical excellence stated that oral atypical anti-psychotic drugs should be considered in the choice of first-line treatments for individuals with newly diagnosed schizophrenia and where there are unacceptable side effects with the typical anti-psychotics in people with a more long-established schizophrenic illness.

Secondary information